Champions Oncology (CSBR) 10-Q 14 Mar 14 2014 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Jan. 31, 2014	Feb. 28, 2014
Document Information [Line Items]	'	'
Entity Registrant Name	'CHAMPIONS ONCOLOGY, INC.	'
Entity Central Index Key	'0000771856	'
Current Fiscal Year End Date	'--04-30	'
Entity Filer Category	'Smaller Reporting Company	'
Trading Symbol	'CSBR	'
Entity Common Stock, Shares Outstanding	'	66,867,100
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Jan-14	'
Document Fiscal Period Focus	'Q3	'
Document Fiscal Year Focus	'2014	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Jan. 31, 2014	Apr. 30, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$5,812	$9,561
Accounts receivable, net	3,123	500
Prepaid expenses and other current assets	281	315
Total current assets	9,216	10,376
Restricted cash	165	192
Property and equipment, net	421	414
Goodwill	669	669
Total assets	10,471	11,651
Current liabilities:	'	'
Accounts payable	937	1,204
Accrued liabilities	705	611
Deferred revenue	2,095	1,114
Total current liabilities	3,737	2,929
Warrant liability	2,248	1,046
Total liabilities	5,985	3,975
Commitments and contingencies	'	'
Redeemable common stock; $0.001 par value; nil and 31,133,333 contingently puttable common shares outstanding as of January 31, 2014 and April 30, 2013 respectively	0	16,882
Stockholders' equity (deficit):	'	'
Common stock, $.001 par value; 125,000,000 shares authorized, including redeemable common stock, 70,103,336 and 38,955,003 shares issued and 66,867,100 and 35,718,767 shares outstanding as of January 31, 2014 and April 30, 2013, respectively	70	39
Treasury stock, at cost, 3,236,236 common shares as of January 31, 2014 and April 30, 2013	-1,252	-1,252
Additional paid-in capital	42,409	23,580
Accumulated deficit	-36,617	-31,473
Accumulated other comprehensive loss	-124	-100
Total stockholders' equity (deficit)	4,486	-9,206
Total liabilities, redeemable common stock and stockholders' equity (deficit)	$10,471	$11,651

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Jan. 31, 2014	Apr. 30, 2013
Redeemable common stock, par value (in dollars per share)	$0.00	$0.00
Redeemable common stock, contingently puttable common shares outstanding	0	31,133,333
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized, including redeemable common stock	125,000,000	125,000,000
Common stock, shares issued	70,103,336	38,955,003
Common stock, shares outstanding	66,867,100	35,718,767
Treasury stock, common shares	3,236,236	3,236,236

UNAUDITED_CONDENSED_CONSOLIDAT

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Jan. 31, 2014	Jan. 31, 2013	Jan. 31, 2014	Jan. 31, 2013
Operating revenue:	'	'	'	'
Personalized oncology solutions	$590	$473	$1,834	$1,850
Translational oncology solutions	3,100	2,444	7,258	4,631
Total operating revenue	3,690	2,917	9,092	6,481
Costs and operating expenses:	'	'	'	'
Cost of personalized oncology solutions	614	676	2,139	2,030
Cost of translational oncology solutions	1,008	566	2,585	1,740
Research and development	535	592	1,614	1,415
Sales and marketing	821	658	2,160	2,047
General and administrative	2,120	1,145	4,476	3,484
Total costs and operating expenses	5,098	3,637	12,974	10,716
Loss from operations	-1,408	-720	-3,882	-4,235
Other income (expense):	'	'	'	'
Change in fair value of warrant liability	846	-255	-1,202	-21
Other (expense)	-7	-10	-37	-22
Total other income (expense)	839	-265	-1,239	-43
Loss before provision for income taxes	-569	-985	-5,121	-4,278
Provision for income taxes	5	5	13	6
Net loss	($574)	($990)	($5,134)	($4,284)
Net loss per common share outstanding, including redeemable common stock, basic and diluted (in dollars per share)	($0.01)	($0.02)	($0.08)	($0.09)
Weighted average common shares outstanding, including redeemable common stock, basic and diluted (in shares)	66,867,114	47,737,000	66,860,792	47,294,000

UNAUDITED_CONDENSED_CONSOLIDAT1

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Jan. 31, 2014	Jan. 31, 2013	Jan. 31, 2014	Jan. 31, 2013
Net loss	($574)	($990)	($5,134)	($4,284)
Foreign currency translation adjustment	1	1	-23	24
Comprehensive loss	($573)	($989)	($5,157)	($4,260)

UNAUDITED_CONDENSED_CONSOLIDAT2

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Jan. 31, 2014	Jan. 31, 2013
Operating activities:	'	'
Net loss	($5,134)	($4,284)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Stock-based compensation expense	1,968	1,934
Depreciation expense	158	153
Change in fair value of warrant liability	1,202	21
Changes in operating assets and liabilities:	'	'
Accounts receivable	-2,623	-58
Prepaid expenses, deposits and other	34	-96
Restricted cash	28	-2
Accounts payable	-266	-574
Accrued liabilities	94	-58
Deferred revenue	981	-168
Net cash used in operating activities	-3,558	-3,132
Investing activities:	'	'
Purchase of property and equipment	-164	-35
Net cash used in investing activities	-164	-35
Financing activities:	'	'
Private placement of common shares and warrants	0	9,195
Proceeds from exercise of options and warrants	'	0
Net cash used in financing activities	0	9,195
Exchange rate effect on cash and cash equivalents	-27	25
(Decrease) increase in cash and cash equivalents	-3,749	6,053
Cash and cash equivalents, beginning of period	9,561	4,716
Cash and cash equivalents, end of period	$5,812	$10,769

Organization_Use_of_Estimates_

Organization, Use of Estimates and Basis of Presentation	9 Months Ended
	Jan. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	'
	Note 1.  Organization, Use of Estimates and Basis of Presentation
	Champions Oncology, Inc. or the Company, is engaged in the development of advanced technology solutions and products to personalize the development and use of oncology drugs. The Company’s TumorGraft Technology Platform is a novel approach to personalizing cancer care, based upon the implantation of human tumors in immune-deficient mice. The Company uses this technology, in conjunction with related services, to offer solutions for two customer groups:
		·	Our Personalized Oncology Solutions, or POS, business, which provides services to physicians and patients looking for information to help guide the development of personalized treatment plans.
		·	Our Translational Oncology Solutions, or TOS, business, which provides services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development that will lower costs and increase the speed of developing new drugs, as well as increase the adoption of existing drugs.
	The Company has three operating subsidiaries: Champions Oncology (Israel), Limited, Champions Biotechnology U.K., Limited and Champions Oncology Singapore, PTE LTD. To date, there have been no material revenues earned by these subsidiaries.
	The financial statements of the Company’s foreign subsidiaries, all of which have a functional currency other than the U.S. dollar, have been translated into the U.S. dollar for the Company’s consolidated financial statements for each period being presented. Translation gains and losses are recognized as a component of accumulated other comprehensive loss in the accompanying consolidated balance sheets. Transaction gains and losses are recognized in earnings. The Company is subject to foreign exchange rate fluctuations in connection with the Company’s international operations.
	These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission or the SEC. All significant intercompany transactions and accounts have been eliminated. All figures are presented in thousands of U.S. dollars, except share data, or except where expressly stated otherwise. Certain information related to the Company’s organization, significant accounting policies and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States or GAAP has been condensed or omitted. The accounting policies followed in the preparation of these unaudited condensed consolidated financial statements are consistent with those followed in the Company’s annual consolidated financial statements for the year ended April 30, 2013, as filed on Form 10-K. In the opinion of management, these unaudited condensed consolidated financial statements contain all material adjustments necessary to fairly state our financial position, results of operations and cash flows for the periods presented and the presentations and disclosures herein are adequate when read in conjunction with the Company’s Annual Report on Form 10-K for the year ended April 30, 2013.
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
	Basic loss per share is calculated by dividing loss available to common shareholders by the weighted average number of common shares (including redeemable common stock) outstanding for the year.  Diluted loss per share is calculated based on the weighted average number of common shares (including redeemable common stock) outstanding for the year, plus the dilutive effect of common stock purchase warrants, stock options and restricted stock units using the treasury stock method.  Contingently issuable shares are included in the calculation of basic earnings per share when all contingencies surrounding the issuance of the shares are met and the shares are issued or issuable.  Contingently issuable shares are included in the calculation of dilutive earnings per share as of the beginning of the reporting period if, at the end of the reporting period, all contingencies surrounding the issuance of the shares are satisfied or would be satisfied if the end of the reporting period were the end of the contingency period.  Due to the net losses for the three and nine months ended January 31, 2014 and 2013, basic and diluted loss per share were the same, as the effect of potentially dilutive securities would have been anti-dilutive.
	The following table reflects the total potential share-based instruments outstanding at January 31, 2014 and 2013 that could have an effect on the future computation of dilution per common share:
			January 31,
			2014		2013
	Stock options			22,633,955		15,018,955
	Warrants			3,276,667		3,276,667
	Restricted stock			-		75,000
	Total common stock equivalents			25,910,622		18,370,622
	Critical Accounting Estimates
	During the current quarter the Company entered into certain contracts that require future performance in the event that a portion of the contract has not been satisfied. Due to such requirements the Company has estimated an amount of revenue related to future performance and has deferred this revenue until all provisions of the agreement have been met. As of January 31, 2014, the Company has deferred $259,000 related to this estimate.

Property_and_Equipment

Property and Equipment	9 Months Ended
	Jan. 31, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	Note 2. Property and Equipment
	Property and equipment is recorded at cost and consists of laboratory equipment, furniture and fixtures, and computer hardware and software. Depreciation is calculated on a straight-line basis over the estimated useful lives of the various assets ranging from three to seven years. Property and equipment consisted of the following (in thousands):
		January 31,		April 30,
		2014		2013
			(unaudited)
	Furniture and fixtures	$	62	$	59
	Computer equipment and software		633		549
	Laboratory equipment		257		179
	Leasehold improvements		2		2
	Total property and equipment		954		789
	Less: Accumulated depreciation		-533		-375
	Property and equipment, net	$	421	$	414
	Depreciation expense was $56,000 and $51,000 for the three months ended January 31, 2014 and 2013, respectively, and $158,000 and $153,000 for the nine months ended January 31, 2014 and 2013, respectively.

ShareBased_Payments

Share-Based Payments	9 Months Ended
	Jan. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	Note 3. Share-Based Payments
	The Company has in place a 2010 Equity Incentive Plan and a 2008 Equity Incentive Plan. In general, these plans provide for stock-based compensation in the form (i) Non-statutory Stock Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights to the Company’s employees, directors and non-employees. The plans also provide for limits on the aggregate number of shares that may be granted, the term of grants and the strike price of option awards.
	Stock-based compensation in the amount of $941,000 and $570,000 was recognized for the three months ended January 31, 2014 and 2013, respectively, and $1,968,000 and $1,934,000 for the nine months ended January 31, 2014 and 2013, respectively.  Stock-based compensation expense was recognized as follows (in thousands):
		Three Months Ended				Nine Months Ended
		January 31,				January 31,
		2014		2013		2014		2013
	General and administrative	$	866	$	500	$	1,686	$	1,619
	Sales and marketing		63		56		189		199
	Research and development		4		4		19		33
	TOS cost of sales		2		4		12		16
	POS cost of sales		6		6		62		67
	Total stock-based compensation expense	$	941	$	570	$	1,968	$	1,934
	Stock Option Grants
	Black-Scholes assumptions used to calculate the fair value of options granted during the three and nine months ended January 31, 2014 and 2013 were as follows (in thousands):
		Three Months Ended				Nine Months Ended
		January 31,				January 31,
		2014		2013		2014		2013
	Expected term in years		6-May		6		6-May		6
	Risk-free interest rates		1.4% - 2.1%		0.9% - 1.0%		0.8% - 2.4%		0.8% - 1.0%
	Volatility		97% - 102%		100% - 102%		97% - 102%		99% - 102%
	Dividend yield		0%		0%		0%		0%
	The weighted average fair value of stock options granted during the three months ended January 31, 2014 and 2013 was $0.97 and $0.27, respectively. The weighted average fair value of stock options granted during the nine  months ended January 31, 2014 and 2013 was $0.96 and $0.36, respectively. The Company’s stock options activity for the nine months ended January 31, 2014 is as follows:
										Weighted
								Weighted		Average
				Directors				Average		Remaining		Aggregate
		Non-		and				Exercise		Contractual		Intrinsic
		Employees		Employees		Total		Price		Life (Years)		Value
	Outstanding, May 1, 2013		765,000		13,125,205		13,890,205	$	0.85		7	$	89,000
	Granted		-		8,850,000		8,850,000		1.23		9.7		148,000
	Exercised		-		-15,000		-15,000		0.62
	Forfeited		-		-65,000		-65,000		0.84
	Expired		-		-26,250		-26,250		0.75
	Outstanding, January 31, 2014		765,000		21,868,955		22,633,955		1		7.6		2,224,000
	Vested and expected to vest as of		765,000		21,868,955		22,633,955		1		7.6		2,224,000
	January 31, 2014
	Exercisable as of January 31, 2014		522,292		13,090,203		13,612,495		0.85		6.2		2,132,000
	Included in the balances outstanding in the table above are 3,000,000 options (which vest based on service criteria) granted to the Company’s Chief Executive Officer and its President as of November 5, 2013 as part of their new employment agreements. In addition to the above, there are 3,000,000 additional options granted to the Company’s Chief Executive Officer and President which vest based on both service and performance criteria.  The service-based conditions of these options provide for vesting to occur monthly over a period of three years.  The performance-based conditions have not been finalized as of January 31, 2014.   The service-based options, like all of the Company’s service-based options, are expensed on a straight-line basis.  Since the straight-line method is not available for performance or market-based share-based payments, the 3,000,000 performance-based options will be expensed on an accelerated basis once the Company determines it is probable that the performance-based conditions will be met.
	Restricted Stock Grants
	A summary of the activity related to restricted stock grants is as follows (in thousands):
				Weighted
				Average Grant
				Date Fair Value
		Shares		Per Share
	Nonvested as of May 1, 2013		50,000	$	0.3
	Granted		-		-
	Vested		-50,000		0.3
	Forfeited		-		-
	Expired		-		-
	Nonvested as of January 31, 2014		-		-
	Stock Purchase Warrants
	As of January 31, 2014 and April 30, 2013, the Company had warrants outstanding for the purchase of 3,276,667 shares of its common stock, all of which were exercisable. Of these warrants, 1,266,667 were issued in connection with the April 2011 Private Placement and 1,860,000 were issued in connection with the January 2013 Private Placement and are accounted for as liabilities as further discussed in Note 4. The remaining 150,000 warrants are accounted for as equity instruments and expire on July 31, 2014. Activity related to these warrants, which expire at various dates through April 2016, is summarized as follows (dollars in thousands):
						Weighted
				Weighted		Average
		Number		Average		Remaining		Aggregate
		of		Exercise		Contractual		Intrinsic
		Shares		Price		Life (Years)		Value
	Outstanding, May 1, 2013		3,276,667	$	0.61		3.9		-
	Granted		-		-		-		-
	Exercised		-		-		-		-
	Expired		-		-		-		-
	Outstanding, January 31, 2014		3,276,667	$	0.61		3.2	$	1,265,734

Redeemable_Common_Stock_and_St

Redeemable Common Stock and Stock Purchase Warrants	9 Months Ended
	Jan. 31, 2014
Redeemable Common Stock and Stock Purchase Warrant [Abstract]	'
Redeemable Common Stock and Stock Purchase Warrant [Text Block]	'
	Note 4. Redeemable Common Stock and Stock Purchase Warrants
	On January 28, 2013, the Company entered into a Securities Purchase Agreement with several accredited investors for the sale of an aggregate 18,600,000 shares of the Company’s Common Stock at a purchase price of $0.50 per share, for aggregate proceeds of $9.3 million (net proceeds of $9.1 million due to issuance costs), $0.5 million of which was sold to officers and directors of the Company. This private placement transaction closed on January 28, 2013. As part of this transaction, the Company also issued warrants to purchase an aggregate 1,860,000 shares of Common Stock at an exercise price of $0.66 per share. These warrants expire five years after the closing date. The Company also entered into an Amended and Restated Registration Rights Agreement on January 28, 2013 that provided certain registration rights with respect to the shares of Common Stock issued and the shares of Common Stock issuable upon exercise of the warrants. Furthermore, certain investors will have the right to require the Company to redeem the purchased common shares held by all of the investors  for cash of $0.50 per share upon a change of control or sale or exclusive license of substantially all of the Company’s assets. The January 2013 Private Placement Put Option will terminate upon the achievement of certain financial milestones by the Company, the sale of 25% of the common shares purchased by an investor, with respect only to the shares owned by such investor, or in certain other circumstances as outlined in the Securities Purchase Agreement for the January 2013 Private Placement. The January 2013 Private Placement investors also have certain participation rights with respect to future financings of the Company. The terms of the January 2013 Private Placement resulted in the issuance of an additional 1,064,658 common shares to the investors of the April 2011 Private Placement under the anti-dilution protections granted such investors, which are discussed below.
	On March 24, 2011, the Company entered into a Securities Purchase Agreement with several accredited investors for the sale of an aggregate 12,533,333 shares of the Company’s Common Stock at a purchase price of $0.75 per share, for aggregate proceeds of $9.4 million, $0.5 million of which was sold to officers and directors of the Company. This private placement transaction closed April 4, 2011 . As part of this transaction, the Company also issued warrants to purchase an aggregate 1,266,667 shares of Common Stock at an exercise price of $0.90 per share. These warrants expire five years after the closing date. The Securities Purchase Agreement governing the April 2011 Private Placement contains certain anti-dilution protections for the investors. The Amended and Restated Registration Rights Agreement referenced above provides certain registration rights with respect to the shares of Common Stock issued and the shares of Common Stock issuable upon exercise of the warrants. Furthermore, certain investors have the right to require the Company to redeem the purchased common shares held by all of the investors  for cash for $0.75 per share upon a change of control or sale or exclusive license of substantially all of the Company’s assets. The April 2011 Private Placement Put Option will terminate upon the achievement of certain financial milestones by the Company, the sale of 25% of the common shares purchased by an investor, with respect only to the shares owned by such investor, or in certain other circumstances as outlined in the Securities Purchase Agreement for the April 2011 Private Placement.
	Due to the April 2011 Private Placement Put Option and the January 2013 Private Placement Put Option described above, the Company has accounted for the Common Stock for the April 2011 Private Placement and January 2013 Private Placement as temporary equity, which is reflected under the caption “redeemable common stock” on the accompanying consolidated balance sheets. The total amount allocated to the redeemable common stock was $8.8 million for the January 2013 Private Placement and $8.2 million for the April 2011 Private Placement. For the January 2013 Private Placement, this allocation is equal to the total proceeds of $9.3 million less the amount allocated to the warrants of $0.4 million and is also net of the direct and incremental costs associated with the January 2013 Private Placement of $0.2 million. For the April 2011 Private Placement, this allocation is equal to the total proceeds of $9.4 million, less the amount allocated to the warrants of $0.9 million and is also net of direct and incremental costs associated with the April 2011 Private Placement of $0.3 million.
	On January 29, 2014, the Company executed amendments to the 2011 Securities Purchase Agreement and to the 2013 Securities Purchase Agreement with certain of the parties thereto, in each case revising the definition of “Change of Control” as it appears on the Securities Purchase Agreements.
	On January 29, 2014, the Company also entered into an agreement with Joel Ackerman, its Chief Executive Officer and a Director, and Ronnie Morris, its President and a Director, both of whom bought securities from the Company pursuant to the Securities Purchase Agreements, that, if the Company’s Board of Directors votes on a transaction, event or approval that would constitute a Put Option Trigger Event (as defined in each of the Securities Purchase Agreements), each of Ackerman and Morris shall either (a) recuse themselves from voting as a member of the Board of Directors on such transaction, event or approval or (b) be entitled to vote but forego exercising or receiving the benefit of their Put Right (as defined in each of the Securities Purchase Agreements).
	Prior to the January 29, 2014 amendments the Put Option Trigger Event (as defined in each of the Securities Purchase Agreements) was outside of the Company’s control.  Subsequent to the January 29, 2014 amendments the Put Option Trigger Event is within the Company’s control.  This change resulted in the common stock related to the April 2011 Private Placement and the 2013 Private Placement to be reclassified from outside of permanent equity (reflected under the caption “redeemable common stock”) to inside permanent equity (reflected in the captions “common stock” and “additional paid-in capital”).
	The warrants issued in connection with both the April 2011 Private Placement and January 2013 Private Placement contain certain exercise price reset provisions. Under these provisions, the exercise price of the warrants may be adjusted downward should the Company have future sales of its Common Stock for no consideration or for a consideration per share less than the Per Share Price (as such term is defined in the April 2011 Private Placement and January 2013 Private Placement). These exercise price reset provisions resulted in a downward adjustment to the exercise price of the warrants issued in the April 2011 Private Placement from $0.90 to $0.50 in January 2013 as a result of the January 2013 Private Placement.
	The Company has accounted for the warrants issued in connection with the April 2011 Private Placement and January 2013 Private Placement as a liability based on the exercise price reset provisions described above. This liability, which is recorded at fair value on the accompanying consolidated balance sheets, totaled $0.8 million at the time of the close of the January 2013 Private Placement Agreement. As of January 31, 2014 and April 30, 2013, the fair value of these warrants was $2.25 million and $1.05 million, respectively. The change in fair value of these warrants has been, and will be, recognized as other income (expense) on the Company’s consolidated statements of operations. The fair value of these warrants was calculated by the Monte Carlo simulation valuation method. Assumptions used to calculate the fair value of these warrants were as follows:
		January 31,		April 30,
		2014		2013
	Expected term in years		2.2 & 3.9		2.9 & 4.7
	Risk-free interest rates		0.7% & 1.5%		0.30%
	Volatility		93% & 107%		95% & 98%
	Dividend yield		0%		0%
	In addition to the assumptions above, the Company also takes into consideration whether or not the Company would participate in another round of financing and if that financing is registered or not and what that stock price would be for the financing at that time. The Company will continue to adjust the warrant liability for changes in fair value until the earlier of the exercise of the warrants, at which time the liability will be reclassified to stockholders' equity, or expiration of the warrants.
	The Company has granted demand registration rights in connection with the investment in common shares and the common shares underlying the warrants for both the April 2011 Private Placement and January 2013 Private Placement. These rights include the requirement of the Company to file certain registration statements within a specified time period and to have these registration statements declared effective within a specified time period. If the Company is not able to comply with these registration requirements, the Company will be required to pay cash penalties equal to 1.0% of the aggregate Purchase Price paid by the investors for each 30-day period in which a Registration Default, as defined in the Securities Purchase Agreement, exists. These penalties are subject to a 10% limit of the aggregate Purchase Price paid by the investors. The Company may become subject to these penalty provisions if it fails to have a registration statement for the common shares declared effective, or to maintain the effectiveness of such registration statement. The total amount of potential penalties under this registration payment arrangement ranges from $50,000 to $130,000 for each 30-day period in which a registration default exists; however, as of January 31, 2014 and April 30, 2013, and through the date of this filing, the Company does not believe these penalties to be probable and accordingly, has not established an accrual for such registration payment arrangements.

Related_Party_Transactions

Related Party Transactions	9 Months Ended
	Jan. 31, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	Note 5. Related Party Transactions
	Related party transactions include transactions between the Company and its shareholders, management, or affiliates.  The following transactions were in the normal course of operations and were measured at the exchange amount, which is the amount of consideration established and agreed to by the parties.
	Consulting Services
	During the nine months ended January 31, 2014 and 2013, the Company paid one of its former directors and former Chief Executive Officer, $0 and $30,000, respectively, in consulting fees.  During the nine months ended January 31, 2014 and 2013, the Company paid certain members of its Board of Directors $115,125 and $122,500, respectively, for consulting services unrelated to their duties as board members. During the nine months ended January 31, 2014 and 2013, the Company paid a substantial stockholder and former member of its Board of Directors $1,000 and $3,000, respectively, for consulting services. During the nine months ended January 31, 2014, the Company received from one of its former directors and former Chief Executive Officer, $25,000 in panel revenue. All of the amounts paid to and received from these related parties have been recognized in revenue and expense.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Jan. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	Note 6. Commitments and Contingencies
	Operating Leases
	As of January 31, 2014, we lease the following facilities under non-cancelable operating lease agreements:
	·      One University Plaza, Suite 307, Hackensack, New Jersey 07601, which, since November 2011, serves as the Company’s corporate headquarters. The lease expires in November 2016. The Company recognized $53,000 and $52,000 of rental costs relative to this lease for the nine months ended January 31, 2014 and 2013, respectively.
	·      855 North Wolfe Street, Suite 619, Baltimore, Maryland 21205, which consists of laboratories and office space where the Company conducts operations related to its primary service offerings.  This lease expires in June 2014. The Company recognized $64,000 and $69,000 of rental costs relative to this lease for the nine months ended January 31, 2014 and 2013, respectively.
	·      17 Hatidhar Street, Ra’anana, Israel, which served as office headquarters for Champions Oncology, Israel. The Company recognized $6,000 and $21,000 of rental costs relative to this lease for the nine months ended January 31, 2014 and 2013, respectively. This lease expired in July 2013 and was not renewed. Following the expiration of this lease, the Company utilizes office space on a limited basis from one of its stockholders. The fair value of rental costs associated with the new office space is immaterial.
	·      57 Mohamed Sultan Road, Singapore, which serves as office headquarters for Champions Oncology, Singapore. The lease was renewed for one year and expires in January 2015. We incurred $4,000 and 1,000 of rental expense for the nine months ended January 31, 2014 and 2013, respectively.
	Legal Matters
	The Company is not currently party to any legal matters to its knowledge. The Company is not aware of any other matters that would have a material impact on the Company’s financial position or results of operations.
	Registration Payment Arrangements
	The Company has entered into an Amended and Restated Registration Rights Agreement in connection with the April 2011 Private Placement and January 2013 Private Placement and is discussed more fully in Note 4. This Amended and Restated Registration Rights Agreement contains provisions that may call for the Company to pay penalties in certain circumstances. This registration payment arrangement primarily relates to the Company’s ability to file a registration statement within a particular time period, have a registration statement declared effective within a particular time period and to maintain the effectiveness of the registration statement for a particular time period. The Company does not believe it is probable that penalty payments will be made for the Amended and Restated Registration Rights Agreement discussed in Note 4 and, accordingly, has not accrued for such potential penalties as of January 31, 2014 and April 30, 2013.

Licensing_Agreements

Licensing Agreements	9 Months Ended
	Jan. 31, 2014
Licensing Agreements [Abstract]	'
Licensing Agreements Disclosure [Text Block]	'
	Note 7. Licensing Agreements
	In February 2010, the Company entered into an exclusive option agreement with a Canadian company. The option agreement granted the Company the exclusive right to review Irinophore C, a nanoparticle drug compound, for the treatment of various forms of cancer, including melanoma, prostate, breast, and lung cancer through April 2011. During the option year, the Company performed various TumorGraft tests on the nanoparticle compound. In March 2011, the Company exercised its option to license Irinophore C, a liposomal formulation of Irinotecan. On the first anniversary of the agreement (March 2012), an additional license fee of $45,000 (Canadian) became due, which was recognized as a liability as of April 30, 2012 and was satisfied during the year ended April 30, 2013. Commencing with the second anniversary of the agreement (March 2013), the Company is obligated to pay a minimum annual royalty of $10,000 (Canadian), unless the agreement were terminated by either party in advance of the anniversary date. Under the terms of the license agreement, the Company will be required to pay up to $3.0 million in development milestones, if achieved. The Company does not believe development milestones will be achieved within the next 12 months. Upon commercialization, the Company would also be required to make royalty and sales milestone payments based upon revenues. As of April 30, 2013 the Company has paid the March 2013 annual royalty payment of $10,000 (Canadian). No accrual has been made for current year royalty payment due in March 2014.

Teva_Agreement

Teva Agreement	9 Months Ended
	Jan. 31, 2014
Teva Agreement [Abstract]	'
Teva Agreement [Text Block]	'
	Note 8. Teva Agreement
	On March 16, 2011, the Company entered into an agreement with Cephalon, Inc., a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd., pursuant to which the Company agreed to conduct TumorGraft studies on two proprietary chemical compounds provided by Cephalon to determine the activity or response of these compounds in potential clinical indications. Under the agreement, Cephalon agreed to, under certain conditions, pay the Company various amounts upon achieving certain milestones, based on the performance of the compounds in preclinical testing and dependent upon testing the compound in clinical settings and obtaining FDA approval. Potential milestone payments that could be received under the agreement total $27 million per compound. In addition, Cephalon agreed to pay the Company royalties on any commercialized products developed under the agreement. Under certain conditions, Cephalon reserved the right to exercise and pay a one-time fee of in lieu of the milestone or royalty payments, which are $460,000 for one compound and $880,000 for the other compound.
	On November 30, 2012, Cephalon exercised the option to pay this one-time fee of $880,000 to the Company, in lieu of any future milestone or royalty payments, for one compound tested under the agreement described above. Written notice was provided to the Company on December 3, 2012 and payment was received on December 19, 2012. This fee was recognized as revenue during the third quarter of fiscal 2013. As of January 31, 2014, the remaining compound is no longer being evaluated.
	During fiscal 2013, the agreement with Cephalon was amended to perform additional work for an increased fee of $277,000. As models, along with required reports, are delivered, revenue is recognized on a proportionate basis in accordance with the Company’s revenue recognition policies. Revenues of $133,000 and $317,000 were recognized during the nine months ended January 31, 2014 and 2013, respectively, which are independent of the $880,000 noted above.
	On July 30, 2013, the Company entered into an agreement with Teva Pharmaceutical Industries Ltd., pursuant to which the Company agreed to conduct TumorGraft studies on multiple proprietary chemical compounds provided by Teva to determine the activity or response of these compounds in potential clinical indications. Under the agreement, Teva agreed to pay an upfront payment and, under certain conditions, pay the Company various amounts upon achieving certain milestones, based on the performance of the compounds in preclinical testing and dependent upon testing the compound in clinical settings and obtaining FDA approval. In addition, Cephalon agreed to pay the Company royalties on any commercialized products developed under the agreement. This agreement terminated the collaborative agreement noted above between Cephalon and the Company. As of January 31, 2014 no revenue has been recognized.

Fair_Value

Fair Value	9 Months Ended
	Jan. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
	Note 9. Fair Value
	The carrying value of cash and cash equivalents, accounts receivable, prepaid expenses, deposits and other receivables, accounts payable, and accrued liabilities approximate their fair value based on the liquidity or the short-term maturities of these instruments. The fair value hierarchy promulgated by GAAP consists of three levels:
	·      Level one — Quoted market prices in active markets for identical assets or liabilities;
	·      Level two — Inputs other than level one inputs that are either directly or indirectly observable; and
	·      Level three — Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.
	Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter. The Company has one liability measured at fair value on a recurring basis, which are warrants that were issued in connection with private placements of the Company’s securities that are discussed more fully in Note 4. As of January 31, 2014 and April 30, 2013, these warrants had an estimated fair value of $2,248,000 and $1,046,000, respectively, which was calculated by the Monte Carlo simulation valuation method using level three inputs. The Company has no assets that are measured at fair value on a recurring basis and there were no assets or liabilities measured at fair value on a non-recurring basis as of January 31, 2014 and April 30, 2013 or during the nine months ended January 31, 2014 and 2013.
	The following table presents information about our warrants liability, which was our only financial instrument measured at fair value on a recurring basis using significant unobservable inputs (Level 3) as of January 31, 2014 (in thousands):
	Balance, May 1, 2013	$	-1,046
	Transfers to (from) Level 3		-
	Total (gains) losses included in earnings		-1,202
	Purchases, issuances and settlements, net		-
	Balance, January 31, 2014	$	-2,248

Business_Segment_Information

Business Segment Information	9 Months Ended
	Jan. 31, 2014
Segment Reporting [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	Note 10. Business Segment Information
	The Company operates in two segments, POS and TOS. The accounting policies of the Company’s segments are the same as those described in Note 2 of the Company’s annual financial statements for the year ended April 30, 2013, as filed on Form 10-K. The Company evaluates performance of its segments based on profit or loss from operations before stock compensation expense, depreciation and amortization, interest expense, interest income, gain on sale of assets, special charges or benefits, and income taxes. Management uses segment profit information for internal reporting and control purposes and considers it important in making decisions regarding the allocation of capital and other resources, risk assessment, and employee compensation, among other matters. The following tables summarize, for the periods indicated, operating results by business segment (in thousands):
		Personalized		Translational
		Oncology		Oncology		Unallocated
		Solutions		Solutions		Corporate
	Three Months Ended January 31, 2014	(POS)		(TOS)		Overhead		Consolidated
	Net revenue	$	590	$	3,100	$	-	$	3,690
	Direct cost of services		-608		-1,007		-		-1,615
	Sales and marketing costs		-405		-352		-		-757
	Other operating expenses		-		-531		-1,254		-1,785
	Stock- based compensation expense (1)		-				-941		-941
	Segment profit (loss)	$	-423	$	1,210	$	-2,195	$	-1,408
		Personalized		Translational
		Oncology		Oncology		Unallocated
		Solutions		Solutions		corporate
	Three Months Ended January 31, 2013	(POS)		(TOS)		Overhead		Consolidated
	Net revenue	$	473	$	2,444	$	-	$	2,917
	Direct cost of services		-661		-561		-		-1,222
	Sales and marketing costs		-361		-220		-		-581
	Other operating expenses		-		-627		-637		-1,264
	Stock- based compensation expense (1)		-		-		-570		-570
	Segment profit (loss)	$	-549	$	1,036	$	-1,207	$	-720
		Personalized		Translational
		Oncology		Oncology		Unallocated
		Solutions		Solutions		Corporate
	Nine Months Ended January 31, 2014	(POS)		(TOS)		Overhead		Consolidated
	Net revenue	$	1,834	$	7,258	$	-	$	9,092
	Direct cost of services		-2,078		-2,572		-		-4,650
	Sales and marketing costs		-1,159		-812		-		-1,971
	Other operating expenses		-		-1,595		-2,790		-4,385
	Stock- based compensation expense (1)		-		-		-1,968		-1,968
	Segment profit (loss)	$	-1,403	$	2,279	$	-4,758	$	-3,882
		Personalized		Translational
		Oncology		Oncology		Unallocated
		Solutions		Solutions		Corporate
	Nine Months Ended January 31, 2013	(POS)		(TOS)		Overhead		Consolidated
	Net revenue	$	1,850	$	4,631	$	-	$	6,481
	Direct cost of services		-2,030		-1,740		-		-3,770
	Sales and marketing costs		-495		-636		-		-1,131
	Other operating expenses		-		-1,463		-2,418		-3,881
	Stock- based compensation expense (1)		-		-		-1,934		-1,934
	Segment profit (loss)	$	-675	$	792	$	-4,352	$	-4,235
	(1) Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.
	All of the Company’s revenue is recorded in the United States and substantially all of its long-lived assets are in the United States.

Organization_Use_of_Estimates_1

Organization, Use of Estimates and Basis of Presentation (Tables)	9 Months Ended
	Jan. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
	The following table reflects the total potential share-based instruments outstanding at January 31, 2014 and 2013 that could have an effect on the future computation of dilution per common share:
		January 31,
		2014		2013
	Stock options		22,633,955		15,018,955
	Warrants		3,276,667		3,276,667
	Restricted stock		-		75,000
	Total common stock equivalents		25,910,622		18,370,622

Property_and_Equipment_Tables

Property and Equipment (Tables)	9 Months Ended
	Jan. 31, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
	Property and equipment consisted of the following (in thousands):
		January 31,		April 30,
		2014		2013
			(unaudited)
	Furniture and fixtures	$	62	$	59
	Computer equipment and software		633		549
	Laboratory equipment		257		179
	Leasehold improvements		2		2
	Total property and equipment		954		789
	Less: Accumulated depreciation		-533		-375
	Property and equipment, net	$	421	$	414

ShareBased_Payments_Tables

Share-Based Payments (Tables)	9 Months Ended
	Jan. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
	Stock-based compensation expense was recognized as follows (in thousands):
		Three Months Ended				Nine Months Ended
		January 31,				January 31,
		2014		2013		2014		2013
	General and administrative	$	866	$	500	$	1,686	$	1,619
	Sales and marketing		63		56		189		199
	Research and development		4		4		19		33
	TOS cost of sales		2		4		12		16
	POS cost of sales		6		6		62		67
	Total stock-based compensation expense	$	941	$	570	$	1,968	$	1,934
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
	Black-Scholes assumptions used to calculate the fair value of options granted during the three and nine months ended January 31, 2014 and 2013 were as follows (in thousands):
		Three Months Ended				Nine Months Ended
		January 31,				January 31,
		2014		2013		2014		2013
	Expected term in years		6-May		6		6-May		6
	Risk-free interest rates		1.4% - 2.1%		0.9% - 1.0%		0.8% - 2.4%		0.8% - 1.0%
	Volatility		97% - 102%		100% - 102%		97% - 102%		99% - 102%
	Dividend yield		0%		0%		0%		0%
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	The Company’s stock options activity for the nine months ended January 31, 2014 is as follows:
										Weighted
								Weighted		Average
				Directors				Average		Remaining		Aggregate
		Non-		and				Exercise		Contractual		Intrinsic
		Employees		Employees		Total		Price		Life (Years)		Value
	Outstanding, May 1, 2013		765,000		13,125,205		13,890,205	$	0.85		7	$	89,000
	Granted		-		8,850,000		8,850,000		1.23		9.7		148,000
	Exercised		-		-15,000		-15,000		0.62
	Forfeited		-		-65,000		-65,000		0.84
	Expired		-		-26,250		-26,250		0.75
	Outstanding, January 31, 2014		765,000		21,868,955		22,633,955		1		7.6		2,224,000
	Vested and expected to vest as of		765,000		21,868,955		22,633,955		1		7.6		2,224,000
	January 31, 2014
	Exercisable as of January 31, 2014		522,292		13,090,203		13,612,495		0.85		6.2		2,132,000
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	'
	A summary of the activity related to restricted stock grants is as follows (in thousands):
				Weighted
				Average Grant
				Date Fair Value
		Shares		Per Share
	Nonvested as of May 1, 2013		50,000	$	0.3
	Granted		-		-
	Vested		-50,000		0.3
	Forfeited		-		-
	Expired		-		-
	Nonvested as of January 31, 2014		-		-
Schedule Of Share Based Compensation Warrants Activity [Table Text Block]	'
	Activity related to these warrants, which expire at various dates through April 2016, is summarized as follows (dollars in thousands):
						Weighted
				Weighted		Average
		Number		Average		Remaining		Aggregate
		of		Exercise		Contractual		Intrinsic
		Shares		Price		Life (Years)		Value
	Outstanding, May 1, 2013.		3,276,667	$	0.61		3.9	$	-
	Granted		-		-		-		-
	Exercised		-		-		-		-
	Expired		-		-		-		-
	Outstanding, January 31, 2014.		3,276,667	$	0.61		3.2	$	1,265,734

Redeemable_Common_Stock_and_St1

Redeemable Common Stock and Stock Purchase Warrants (Tables)	9 Months Ended
	Jan. 31, 2014
Redeemable Common Stock and Stock Purchase Warrant [Abstract]	'
Schedule of Share-based Payment Award Stock Warrants Valuation Assumptions [Table Text Block]	'
	Assumptions used to calculate the fair value of these warrants were as follows:
		January 31,		April 30,
		2014		2013
	Expected term in years		2.2 & 3.9		2.9 & 4.7
	Risk-free interest rates		0.7% & 1.5%		0.30%
	Volatility		93% & 107%		95% & 98%
	Dividend yield.		0%		0%

Fair_Value_Tables

Fair Value (Tables)	9 Months Ended
	Jan. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	'
	The following table presents information about our warrants liability, which was our only financial instrument measured at fair value on a recurring basis using significant unobservable inputs (Level 3) as of January 31, 2014 (in thousands):
	Balance, May 1, 2013	$	-1,046
	Transfers to (from) Level 3		-
	Total (gains) losses included in earnings		-1,202
	Purchases, issuances and settlements, net		-
	Balance, January 31, 2014	$	-2,248

Business_Segment_Information_T

Business Segment Information (Tables)	9 Months Ended
	Jan. 31, 2014
Segment Reporting [Abstract]	'
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
	The following tables summarize, for the periods indicated, operating results by business segment (in thousands):
		Personalized		Translational
		Oncology		Oncology		Unallocated
		Solutions		Solutions		Corporate
	Three Months Ended January 31, 2014	(POS)		(TOS)		Overhead		Consolidated
	Net revenue	$	590	$	3,100	$	-	$	3,690
	Direct cost of services		-608		-1,007		-		-1,615
	Sales and marketing costs		-405		-352		-		-757
	Other operating expenses		-		-531		-1,254		-1,785
	Stock- based compensation expense (1)		-				-941		-941
	Segment profit (loss)	$	-423	$	1,210	$	-2,195	$	-1,408
		Personalized		Translational
		Oncology		Oncology		Unallocated
		Solutions		Solutions		corporate
	Three Months Ended January 31, 2013	(POS)		(TOS)		Overhead		Consolidated
	Net revenue	$	473	$	2,444	$	-	$	2,917
	Direct cost of services		-661		-561		-		-1,222
	Sales and marketing costs		-361		-220		-		-581
	Other operating expenses		-		-627		-637		-1,264
	Stock- based compensation expense (1)		-		-		-570		-570
	Segment profit (loss)	$	-549	$	1,036	$	-1,207	$	-720
		Personalized		Translational
		Oncology		Oncology		Unallocated
		Solutions		Solutions		Corporate
	Nine Months Ended January 31, 2014	(POS)		(TOS)		Overhead		Consolidated
	Net revenue	$	1,834	$	7,258	$	-	$	9,092
	Direct cost of services		-2,078		-2,572		-		-4,650
	Sales and marketing costs		-1,159		-812		-		-1,971
	Other operating expenses		-		-1,595		-2,790		-4,385
	Stock- based compensation expense (1)		-		-		-1,968		-1,968
	Segment profit (loss)	$	-1,403	$	2,279	$	-4,758	$	-3,882
		Personalized		Translational
		Oncology		Oncology		Unallocated
		Solutions		Solutions		Corporate
	Nine Months Ended January 31, 2013	(POS)		(TOS)		Overhead		Consolidated
	Net revenue	$	1,850	$	4,631	$	-	$	6,481
	Direct cost of services		-2,030		-1,740		-		-3,770
	Sales and marketing costs		-495		-636		-		-1,131
	Other operating expenses		-		-1,463		-2,418		-3,881
	Stock- based compensation expense (1)		-		-		-1,934		-1,934
	Segment profit (loss)	$	-675	$	792	$	-4,352	$	-4,235
	(1) Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.

Organization_Use_of_Estimates_2

Organization, Use of Estimates and Basis of Presentation (Details)	9 Months Ended
	Jan. 31, 2014	Jan. 31, 2013
Common stock equivalents	25,910,622	18,370,622
Employee Stock Option [Member]	'	'
Common stock equivalents	22,633,955	15,018,955
Warrant [Member]	'	'
Common stock equivalents	3,276,667	3,276,667
Restricted Stock [Member]	'	'
Common stock equivalents	0	75,000

Organization_Use_of_Estimates_3

Organization, Use of Estimates and Basis of Presentation (Details Textual) (USD $)	Jan. 31, 2014
Deferred Revenue	$259,000

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Jan. 31, 2014	Apr. 30, 2013
In Thousands, unless otherwise specified
Furniture and fixtures	$62	$59
Computer equipment and software	633	549
Laboratory equipment	257	179
Leasehold improvements	2	2
Total property and equipment	954	789
Less: Accumulated depreciation	-533	-375
Property and equipment, net	$421	$414

Property_and_Equipment_Details1

Property and Equipment (Details Textual) (USD $)	3 Months Ended		9 Months Ended
	Jan. 31, 2014	Jan. 31, 2013	Jan. 31, 2014	Jan. 31, 2013
Depreciation	$56,000	$51,000	$158,000	$153,000

ShareBased_Payments_Details

Share-Based Payments (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Jan. 31, 2014	Jan. 31, 2013	Jan. 31, 2014	Jan. 31, 2013
Stock-based compensation expense	$941	$570	$1,968	$1,934
General and Administrative Expense [Member]	'	'	'	'
Stock-based compensation expense	866	500	1,686	1,619
Selling and Marketing Expense [Member]	'	'	'	'
Stock-based compensation expense	63	56	189	199
Research and Development Expense [Member]	'	'	'	'
Stock-based compensation expense	4	4	19	33
Translational Oncology Solutions Cost of Sales [Member]	'	'	'	'
Stock-based compensation expense	2	4	12	16
Personalized Oncology Solutions Cost of Sales [Member]	'	'	'	'
Stock-based compensation expense	$6	$6	$62	$67

ShareBased_Payments_Details_1

Share-Based Payments (Details 1)	3 Months Ended		9 Months Ended
	Jan. 31, 2014	Jan. 31, 2013	Jan. 31, 2014	Jan. 31, 2013
Expected term in years	'	'6 years	'	'6 years
Dividend yield	0.00%	0.00%	0.00%	0.00%
Minimum [Member]	'	'	'	'
Expected term in years	'5 years	'	'5 years	'
Risk-free interest rates Minimum	1.40%	0.90%	0.80%	0.80%
Volatility Minimum	97.00%	100.00%	97.00%	99.00%
Maximum [Member]	'	'	'	'
Expected term in years	'6 years	'	'6 years	'
Risk-free interest rates Maximum	2.10%	1.00%	2.40%	1.00%
Volatility Maximum	102.00%	102.00%	102.00%	102.00%

ShareBased_Payments_Details_2

Share-Based Payments (Details 2) (USD $)	9 Months Ended	12 Months Ended
	Jan. 31, 2014	Apr. 30, 2013
Shares, Outstanding, Beginning Balance	13,890,205	'
Shares, Granted	8,850,000	'
Shares, Exercised	-15,000	'
Shares, Forfeited	-65,000	'
Shares, Expired	-26,250	'
Shares, Outstanding, Ending Balance	22,633,955	13,890,205
Shares, Vested and expected to vest	22,633,955	'
Shares, Exercisable	13,612,495	'
Weighted Average Exercise Price, Outstanding, Beginning Balance	$0.85	'
Weighted Average Exercise Price, Granted	$1.23	'
Weighted Average Exercise Price, Exercised	$0.62	'
Weighted Average Exercise Price, Forfeited	$0.84	'
Weighted Average Exercise Price, Expired	$0.75	'
Weighted Average Exercise Price, Outstanding, Ending Balance	$1	$0.85
Weighted Average Exercise Price, Vested and expected to vest	$1	'
Weighted Average Exercise Price, Exercisable	$0.85	'
Weighted Average Remaining Contractual Life (Years), Outstanding	'7 years 7 months 6 days	'7 years
Weighted Average Remaining Contractual Life (Years), Granted	'9 years 8 months 12 days	'
Weighted Average Remaining Contractual Life (Years), Vested and expected to vest	'7 years 7 months 6 days	'
Weighted Average Remaining Contractual Life (Years), Exercisable	'6 years 2 months 12 days	'
Aggregate Intrinsic Value, Outstanding, Beginning Balance	$89,000	'
Aggregate Intrinsic Value, Granted	148,000	'
Aggregate Intrinsic Value, Outstanding, Ending Balance	2,224,000	89,000
Aggregate Intrinsic Value, Vested and expected to vest	2,224,000	'
Aggregate Intrinsic Value, Exercisable	$2,132,000	'
Non-Employees [Member]	'	'
Shares, Outstanding, Beginning Balance	765,000	'
Shares, Granted	0	'
Shares, Exercised	0	'
Shares, Forfeited	0	'
Shares, Expired	0	'
Shares, Outstanding, Ending Balance	765,000	'
Shares, Vested and expected to vest	765,000	'
Shares, Exercisable	522,292	'
Directors and Employees [Member]	'	'
Shares, Outstanding, Beginning Balance	13,125,205	'
Shares, Granted	8,850,000	'
Shares, Exercised	-15,000	'
Shares, Forfeited	-65,000	'
Shares, Expired	-26,250	'
Shares, Outstanding, Ending Balance	21,868,955	'
Shares, Vested and expected to vest	21,868,955	'
Shares, Exercisable	13,090,203	'

ShareBased_Payments_Details_3

Share-Based Payments (Details 3) (Restricted Stock [Member], USD $)	9 Months Ended
	Jan. 31, 2014
Restricted Stock [Member]	'
Number of Shares, Beginning Balance	50,000
Shares, Granted	0
Shares, Vested	-50,000
Shares, Forfeited	0
Shares, Expired	0
Number of Shares, Ending Balance	0
Weighted Average Grant Date Fair Value Per Share, Nonvested, Beginning Balance	$0.30
Weighted Average Grant Date Fair Value Per Share, Granted	$0
Weighted Average Grant Date Fair Value Per Share, Vested	$0.30
Weighted Average Grant Date Fair Value Per Share, Forfeited	$0
Weighted Average Grant Date Fair Value Per Share, Expired	$0
Weighted Average Grant Date Fair Value Per Share, Nonvested, Ending Balance	$0

ShareBased_Payments_Details_4

Share-Based Payments (Details 4) (Warrant [Member], USD $)	9 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Jan. 31, 2014	Apr. 30, 2013
Warrant [Member]	'	'
Number of Shares, Beginning Balance	3,276,667	'
Number of Shares, Granted	0	'
Number of Shares, Exercised	0	'
Number of Shares, Expired	0	'
Number of Shares, Ending Balance	3,276,667	3,276,667
Weighted Average Exercise Price, Beginning Balance	$0.61	'
Weighted Average Exercise Price, Granted	$0	'
Weighted Average Exercise Price, Exercised	$0	'
Weighted Average Exercise Price, Expired	$0	'
Weighted Average Exercise Price, Ending Balance	$0.61	$0.61
Weighted Average Remaining Contractual Life (Years)	'3 years 2 months 12 days	'3 years 10 months 24 days
Aggregate Intrinsic Value, Beginning Balance	$0	'
Aggregate Intrinsic Value, Ending Balance	$1,265,734	$0

ShareBased_Payments_Details_Te

Share-Based Payments (Details Textual) (USD $)	3 Months Ended		9 Months Ended
	Jan. 31, 2014	Jan. 31, 2013	Jan. 31, 2014	Jan. 31, 2013	Apr. 30, 2013
Stock-based compensation expense	$941,000	$570,000	$1,968,000	$1,934,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$0.97	$0.27	$0.96	$0.36	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	'	'	8,850,000	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Vesting Period, Fair Value	'	'	$0	'	'
Class of Warrant or Right, Outstanding	3,276,667	'	3,276,667	'	3,276,667
Chief Executive Officer and President [Member]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	'	'	3,000,000	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total	'	'	3,000,000	'	'
April 2011 Private Placement [Member]	'	'	'	'	'
Warrants Issued During Period for Common Stock	'	'	1,266,667	'	'
January 2013 Private Placement [Member]	'	'	'	'	'
Warrants Issued During Period for Common Stock	'	'	1,860,000	'	'
Equity Instrument [Member]	'	'	'	'	'
Class of Warrant or Right, Outstanding	150,000	'	150,000	'	'

Redeemable_Common_Stock_and_St2

Redeemable Common Stock and Stock Purchase Warrants (Details)	9 Months Ended	12 Months Ended
	Jan. 31, 2014	Apr. 30, 2013
Dividend yield	0.00%	0.00%
Minimum [Member]	'	'
Expected term in years	'2 years 2 months 12 days	'2 years 10 months 24 days
Risk-free interest rates	0.70%	'
Volatility	93.00%	95.00%
Maximum [Member]	'	'
Expected term in years	'3 years 10 months 24 days	'4 years 8 months 12 days
Risk-free interest rates	1.50%	0.30%
Volatility	107.00%	98.00%

Redeemable_Common_Stock_and_St3

Redeemable Common Stock and Stock Purchase Warrants (Details Textual) (USD $)	1 Months Ended		9 Months Ended
	Jan. 28, 2013	Mar. 24, 2011	Jan. 31, 2014	Apr. 30, 2013
Stock Issued During Period, Shares, Acquisitions	18,600,000	12,533,333	'	'
Common Stock Purchase Price	$0.50	$0.75	'	'
Stock Issued During Period, Value, Share-based Compensation, Gross	$9,300,000	$9,400,000	'	'
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	500,000	500,000	'	'
Proceeds from Issuance of Common Stock and Warrants	9,100,000	'	'	'
Percentage of Cash Penalties	'	'	1.00%	'
Purchase Price Limit Percentage	'	'	10.00%	'
Estimated Fair Value of Warrants	'	'	2,248,000	1,046,000
Minimum [Member]	'	'	'	'
Potential Penalties Amount	'	'	50,000	'
Maximum [Member]	'	'	'	'
Potential Penalties Amount	'	'	130,000	'
January 2013 Private Placement [Member]	'	'	'	'
Common Stock Purchase Price	'	'	$0.50	'
Warrants Issued During Period for Common Stock	'	'	1,860,000	'
Warrants Exercise Price Per Share	'	'	$0.66	'
Percentage of Common Stock Purchased	'	'	25.00%	'
Issuance of Additional Common Shares to Investors	'	'	1,064,658	'
Net Shares Reclassified to Mandatorily Redeemable Capital Stock, Value	'	'	8,800,000	'
Proceeds from Issuance of Common Stock and Warrants	'	'	9,300,000	'
Proceeds from Issuance of Warrants	'	'	400,000	'
Incremental Compensation Cost	'	'	200,000	'
Warrants and Rights Outstanding	'	'	800,000	'
April 2011 Private Placement [Member]	'	'	'	'
Common Stock Purchase Price	'	'	$0.75	'
Warrants Issued During Period for Common Stock	'	'	1,266,667	'
Warrants Exercise Price Per Share	'	'	$0.90	'
Percentage of Common Stock Purchased	'	'	25.00%	'
Net Shares Reclassified to Mandatorily Redeemable Capital Stock, Value	'	'	8,200,000	'
Proceeds from Issuance of Common Stock and Warrants	'	'	9,400,000	'
Proceeds from Issuance of Warrants	'	'	900,000	'
Incremental Compensation Cost	'	'	$300,000	'
April 2011 Private Placement [Member] | Minimum [Member]	'	'	'	'
Warrants Exercise Price Per Share	'	'	$0.50	'
April 2011 Private Placement [Member] | Maximum [Member]	'	'	'	'
Warrants Exercise Price Per Share	'	'	$0.90	'

Related_Party_Transactions_Det

Related Party Transactions (Details Textual) (USD $)	9 Months Ended
	Jan. 31, 2014	Jan. 31, 2013
Chief Executive Officer [Member]	'	'
Related Party Transaction, Amounts of Transaction	$0	$30,000
Revenue from Related Parties	25,000	'
Board of Directors Chairman [Member]	'	'
Related Party Transaction, Amounts of Transaction	115,125	122,500
Substantial Stockholders [Member]	'	'
Related Party Transaction, Amounts of Transaction	$1,000	$3,000

Commitments_and_Contingencies_

Commitments and Contingencies (Details Textual) (USD $)	9 Months Ended
	Jan. 31, 2014	Jan. 31, 2013
Corporate Headquarters [Member]	'	'
Lease Expiration Date	30-Nov-16	'
Operating Leases, Rent Expense	$53,000	$52,000
Laboratories and Office Space [Member]	'	'
Lease Expiration Date	30-Jun-14	'
Operating Leases, Rent Expense	64,000	69,000
Israel Office Headquarters [Member]	'	'
Lease Expiration Date	31-Jul-13	'
Operating Leases, Rent Expense	6,000	21,000
Singapore Office Headquarters in Singapore [Member]	'	'
Lease Expiration Date	31-Jan-15	'
Operating Leases, Rent Expense	$4,000	$1,000

Licensing_Agreements_Details_T

Licensing Agreements (Details Textual)	12 Months Ended
	Apr. 30, 2013	Apr. 30, 2013	Apr. 30, 2012	Jan. 31, 2014
	USD ($)	CAD	CAD	CAD
License Costs	'	'	45,000	'
Royalty Expense	'	10,000	'	'
Payments to Acquire Productive Assets, Total	3,000,000	'	'	'
Accrued Annual Royalty Payment	'	10,000	'	10,000

Teva_Agreement_Details_Textual

Teva Agreement (Details Textual)	1 Months Ended		9 Months Ended		12 Months Ended	1 Months Ended
	Nov. 30, 2012	Mar. 16, 2011	Jan. 31, 2014	Jan. 31, 2013	Apr. 30, 2013	Mar. 16, 2011	Mar. 16, 2011
	USD ($)	USD ($)	USD ($)	USD ($)	CAD	One Compound [Member]	Second Compound [Member]
						USD ($)	USD ($)
Potential Milestone Payments	'	$27,000,000	'	'	'	'	'
Royalty Expense	'	'	'	'	10,000	460,000	880,000
Exercise of Options to One Time Royalty Fee	880,000	'	880,000	'	'	'	'
Deferred Revenue, Revenue Recognized	'	'	133,000	317,000	'	'	'
Increase (Decrease) in Contract Receivables, Net	'	'	$277,000	'	'	'	'

Fair_Value_Details

Fair Value (Details) (Fair Value, Inputs, Level 3 [Member], USD $)	9 Months Ended
In Thousands, unless otherwise specified	Jan. 31, 2014
Fair Value, Inputs, Level 3 [Member]	'
Balance, May 1, 2013	($1,046)
Transfers to (from) Level 3	0
Total (gains) losses included in earnings	-1,202
Purchases, issuances and settlements, net	0
Balance, January 31, 2014	($2,248)

Fair_Value_Details_Textual

Fair Value (Details Textual) (USD $)	Jan. 31, 2014	Apr. 30, 2013
Estimated Fair Value of Warrants	$2,248,000	$1,046,000

Business_Segment_Information_D

Business Segment Information (Details) (USD $)	3 Months Ended				9 Months Ended
In Thousands, unless otherwise specified	Jan. 31, 2014		Jan. 31, 2013		Jan. 31, 2014		Jan. 31, 2013
Net revenue	$3,690		$2,917		$9,092		$6,481
Sales and marketing costs	-821		-658		-2,160		-2,047
Stock- based compensation expense	-941		-570		-1,968		-1,934
Personalized Oncology Solutions [Member]	'		'		'		'
Net revenue	590		473		1,834		1,850
Direct cost of services	-608		-661		-2,078		-2,030
Sales and marketing costs	-405		-361		-1,159		-495
Other operating expenses	0		0		0		0
Stock- based compensation expense	0	[1]	0	[1]	0	[1]	0	[1]
Segment profit (loss)	-423		-549		-1,403		-675
Translational Oncology Solutions [Member]	'		'		'		'
Net revenue	3,100		2,444		7,258		4,631
Direct cost of services	-1,007		-561		-2,572		-1,740
Sales and marketing costs	-352		-220		-812		-636
Other operating expenses	-531		-627		-1,595		-1,463
Stock- based compensation expense	0	[1]	0	[1]	0	[1]	0	[1]
Segment profit (loss)	1,210		1,036		2,279		792
Unallocated Corporate Overhead [Member]	'		'		'		'
Net revenue	0		0		0		0
Direct cost of services	0		0		0		0
Sales and marketing costs	0		0		0		0
Other operating expenses	-1,254		-637		-2,790		-2,418
Stock- based compensation expense	-941	[1]	-570	[1]	-1,968	[1]	-1,934	[1]
Segment profit (loss)	-2,195		-1,207		-4,758		-4,352
Consolidated [Member]	'		'		'		'
Net revenue	3,690		2,917		9,092		6,481
Direct cost of services	-1,615		-1,222		-4,650		-3,770
Sales and marketing costs	-757		-581		-1,971		-1,131
Other operating expenses	-1,785		-1,264		-4,385		-3,881
Stock- based compensation expense	-941	[1]	-570	[1]	-1,968	[1]	-1,934	[1]
Segment profit (loss)	($1,408)		($720)		($3,882)		($4,235)
[1]	Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.